

Increasing complexity of cancer care:  
How displaced treatments impact efficiency, cost-effectiveness  
and equity

Philip Haywood

MB&ChB (Otago), M.Ec (Sydney), BA (Otago)

A submitted thesis for a Doctor of Philosophy in Health Economics

at the Faculty of Business

University of Technology Sydney

2018



## **Certificate of Original Authorship**

I, Philip Haywood, declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the Business School at the University of Technology Sydney. This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

Production Note:

Signature removed prior to publication.

27<sup>th</sup> October 2018

This research is supported by an Australian Government Research Training Program Scholarship.

The Elements of Cancer Care cohort study was approved by the Human Research Ethics Committee (University of New South Wales, approval number 07014).

## Acknowledgments

This thesis is an outcome of a collective effort. I wish to thank my supervisors, Professor Rosalie Viney, Professor Marion Hass and Dr Melvin Chin, for their time and generosity in reading, discussing and challenging my work in this thesis. I would also like to thank Professor Jane Hall for her mentorship and introduction to the world of health economics. I wish to acknowledge the examiners of the thesis, Professor Stuart Peacock and Professor Andrew Roberts, whose critiques and comments improved the work contained in this thesis.

Robyn Ward, Sallie-Anne Pearson and Ben Daniels were responsible for the Elements of Cancer Care (EoCC) data which formed the basis of several chapters in this thesis. Robyn Ward was responsible for the oncologist's review. Alison Pearce conducted earlier work using the EoCC data. Thank you for these contributions. This research was supported by PhD grants from University of Technology Sydney, CHERE and the Translational Cancer Research Network (TCRN). The TCRN also provided conference funding to attend iHEA to present this work. Wendy Monaghan, Publications Editor ([www.wendymonaghan.com.au](http://www.wendymonaghan.com.au)), copy edited an early draft, with editorial intervention restricted to Standards D and E of the Australian Standards for Editing Practice, as stipulated by the Guidelines for Editing Research Theses.

This research would not have been possible without the participants in the Elements of Cancer Care cohort who gave up their time and consented to the use of their information. I would like to thank them as well. Research such as this thesis would not exist without contributions such as theirs.

Colleagues at the Centre for Health Economics Research and Evaluation (CHERE) - both past and present - provided advice, encouragement and distraction when necessary. Thank you Kees van Gool, Liz Chinchin, Kathleen Manipis, Serena Yu, Thomas Longden, Brendan Mulhern, Jody Church, Bonny Parkinson, Richard De Abreu Lourenco, Stephen Goodall, Paula Cronin and Margie Campbell amongst others. Thank you to the CHERE PhD group as well. I would also like to thank Dr Eric Haywood for reviewing the introductory chapters.

Most of all, I would like to thank my partner, Rachel. As well as Mum, Dad, Jim and Lyn. Thank you to my family and Rachel's family for their time, help and most of all their understanding. I could and would not have been able to finish this without all of you. I dedicate this work to the memory of Ben White, who sadly passed away during its completion.

## Table of contents

Certificate of Original Authorship .....	i
Acknowledgments .....	ii
Table of contents .....	iii
List of figures .....	ix
List of tables .....	xii
Abstract .....	xx
Background .....	xx
Methods .....	xx
Results .....	xx
Conclusions .....	xxi
Abbreviations .....	22
Symbols .....	25
Chapter 1 Introduction .....	1
1.1 What is the problem? .....	1
1.2 Oncology treatment .....	4
1.3 What is the magnitude of the problem? .....	6
1.4 Equity considerations .....	8
1.5 Outline of the thesis .....	9
Chapter 2 Framework and efficiency .....	12
2.1 Framework of lines of therapy .....	12
2.2 Framework of displacement .....	13
2.2.1 Economic evaluation for oncology pharmaceutical adoption .....	17
2.2.2 The importance of correct specification of alternatives in an economic evaluation .....	19
2.3 What are the efficiency implications of displacement? .....	25
2.3.1 Assuming replacement rather than replacement and displacement .....	25
2.3.2 Inclusion of mean costs and benefits with displacement .....	27
2.3.3 Value-based pricing and full information about incremental cost and benefit .....	29

2.4 Conclusions .....	44
Chapter 3 Current literature for economic evaluations in oncology .....	46
3.1 Economic evaluations of multiple lines of therapy in oncology.....	47
3.1.1 Search strategy .....	48
3.1.2 Overview of recovered literature .....	50
3.1.3 Economic evaluations of colorectal cancer .....	58
3.1.4 Economic evaluations of breast cancer .....	60
3.1.5 Economic evaluations of non-small cell lung cancer.....	61
3.1.6 Other relevant articles recovered in the literature search .....	62
3.1.7 Crossover/Switching literature .....	63
3.1.8 Dynamic treatment strategies.....	64
3.1.9 Approach to modelling within the current literature.....	65
3.1.10 Conclusions.....	80
3.2 Cetuximab economic evaluations.....	85
3.2.1 Introduction.....	85
3.2.2 Published systemic reviews of economic evaluations of cetuximab .....	87
3.2.3 Methods .....	89
3.2.4 Results .....	90
3.2.5 Conclusions.....	104
Chapter 4 Estimating the number of lines of therapy.....	109
4.1 Chemotherapy funding and administrative data .....	111
4.1.1 Chemotherapy funding in Australia .....	111
4.1.2 Complexities associated with prescribing and remuneration in the PBS.....	114
4.2 The Elements of Cancer Care (EoCC) cohort .....	115
4.3 Number of lines of therapy received by the EoCC cancer cohort .....	119
4.3.1 Data .....	119
4.3.2 Methods .....	121
4.3.3 Results .....	121

4.3.4 Discussion.....	124
4.4 Validation and completeness of PBS administrative data .....	124
4.4.1 Presence or absence of other section 100 oncology pharmaceuticals .....	124
4.4.2 Completeness of the PBS administrative data.....	126
4.4.3 Explanation of missing pharmaceuticals from PBS data.....	132
4.4.4 Examination of the potential for other administrative data to provide the missing information .....	135
4.4.5 Discussion and conclusion .....	148
4.5 Use of the PBS to estimate the number of lines of therapy .....	150
4.5.1 Methods.....	152
4.5.2 Results.....	154
4.5.3 Discussion and conclusions.....	158
4.6 Conclusions .....	159
Chapter 5 Assessing the costs of lines of therapy.....	161
5.1 Length of time for each line of therapy .....	163
5.1.1 Methods.....	164
5.1.2 Results.....	165
5.1.3 Discussion.....	166
5.2 Resource use and costs.....	167
5.2.1 Pharmaceutical Benefits Scheme.....	168
5.2.2 Medicare Benefits Schedule .....	169
5.2.3 Admitted patient data collection .....	170
5.2.4 Emergency department data collection .....	172
5.2.5 Total costs .....	173
5.2.6 Discussion.....	177
5.3 Combining costs and lines of therapy .....	178
5.3.1 Methods.....	178
5.3.2 Results.....	179

5.3.3 Discussion .....	182
5.4 Econometric analysis of the monthly costs in lines of therapy .....	183
5.4.1 Modelling considerations .....	183
5.4.2 Methods .....	186
5.4.3 Results .....	189
5.4.4 Reduction in costs.....	202
5.4.5 Discussion .....	203
5.5 Conclusions .....	204
Chapter 6 Displacement of protocols and the resulting clinical consequences.....	206
6.1 Available evidence for longer length of treatment sequence .....	207
6.1.1 Methods .....	207
6.1.2 Results .....	208
6.1.3 Discussion .....	212
6.2 Therapeutic options available in Australia over time.....	213
6.2.1 Methods .....	213
6.2.2 Results .....	214
6.2.3 Discussion .....	216
6.3 The effectiveness of displaced protocols .....	216
6.3.1 Methods .....	220
6.3.2 Results .....	223
6.4 Discussion .....	240
6.5 Conclusions.....	244
Chapter 7 Modelling the cost-effectiveness of displacement.....	246
7.1 Simple cost-effectiveness analysis .....	247
7.1.1 Model and structure .....	248
7.1.2 Methods .....	252
7.1.3 Results .....	258
7.1.4 Discussion .....	266



7.2 Probabilistic sensitivity analysis .....	267
7.2.1 Model and structure .....	267
7.2.2 Methods .....	268
7.2.3 Results .....	276
7.3 Conclusions .....	281
Chapter 8 Generalisation and implications.....	286
8.1 Contribution to the literature .....	286
8.2 Moving beyond the displacement framework.....	289
8.3 Recommendations .....	291
8.3.1 Recommendations for future research.....	292
8.3.2 Recommendations for economic evaluations of multiple lines of therapy in oncology .....	292
8.3.3 Recommendations when undertaking research using the PBS and MBS for oncology .....	293
8.3.4 Recommendations for the PBS and the Australian health system .....	294
8.3.5 Recommendations for treatments that may not be cost-effective at any price when displaced .....	294
Appendix A: Review of articles found in search for economic evaluations of multiple lines of therapy.....	296
Appendix B: Detailed data extraction for economic evaluations of multiple lines of therapy. 308	
CRC economic evaluations .....	308
Breast cancer economic evaluations .....	339
NSCLC economic evaluations .....	341
Appendix C: Cetuximab cost-effectiveness analysis .....	346
Economic evaluations of later lines of therapy .....	346
Economic evaluations of cetuximab as first line of therapy .....	373
Economic evaluations involving treatment sequences .....	386
Appendix D: Econometric output .....	392

Appendix E: Literature search for studies with two or more lines of therapy .....	411
Medline search .....	412
EconLit search .....	427
PubMed search .....	433
Appendix F: Data extraction of studies for two or more lines of therapy .....	442
Randomised controlled trials identified in the literature .....	442
Non-randomised trials identified in the literature .....	493
Appendix G: Parameters and detailed sensitivity analysis .....	509
Sensitivity analysis of Section 7.1 .....	509
Parameters for probabilistic sensitivity analysis .....	514
References .....	522

## List of figures

Figure 1: Cost per incremental progression free survival gain over time.....	8
Figure 2: Cost-Effectiveness plane for replacement with treatments A, B and C.....	21
Figure 3: Cost-effectiveness place of replacement and displacement for treatment A and B...	23
Figure 4: Example of displacement resulting in allocative inefficiency .....	28
Figure 5: Value-based pricing of alternative treatments with replacement .....	36
Figure 6: Value-based pricing of A, B and C with replacement and displacement.....	37
Figure 7: Components of Chapter 3.....	47
Figure 8: CONSORT diagram for the literature search of economic evaluations of treatment sequences in carcinomas .....	50
Figure 9: Overall survival breakdown .....	67
Figure 10: CONSORT diagram for the literature search of cetuximab economic evaluations....	90
Figure 11: Incremental cost-effectiveness ratio for cetuximab under different strategies (later line) .....	100
Figure 12: Incremental cost-effectiveness of cetuximab with and without KRAS monitoring.	104
Figure 13: Scheme of Chapter 4.....	110
Figure 14: Data extractions from the EoCC cohort .....	116
Figure 15: PBS identification of oncologist protocols .....	127
Figure 16: Cyclophosphamide scripts in 2009 by four-week months.....	134
Figure 17: Time interval between PBS date of supply and the closest temporal MBS infusion reimbursement .....	138
Figure 18: Time interval between MBS infusion and closest temporal PBS date of supply .....	139
Figure 19: Gap between successive “excess” infusions for metastatic CRC by history of use of high cost pharmaceuticals (HCD) .....	144
Figure 20: Scheme of Chapter 5.....	162
Figure 21: Histogram of total pharmaceutical cost .....	169
Figure 22: Histogram of total costs by participant .....	175
Figure 23: Mean pharmaceutical cost per month in the first line of therapy (for the first 12 months).....	180
Figure 24: Mean total cost per month in the first line of therapy (for the first 12 months) ....	181
Figure 25: Mean cost per month for first three lines of therapy.....	182
Figure 26: Coefficient plots for the time varying variables (logged costs- model 12) .....	194
Figure 27: Lines of therapy coefficients for subgroups of the EoCC (logged cost model 12) ...	195

Figure 28: Lines of therapy coefficients for balanced and prospective only (logged cost model 12).....	196
Figure 29: Estimation of uncontrolled monthly cost in each line of therapy over first 18 months .....	197
Figure 30: Monthly cost in each line of therapy for first 18 months controlled for death, comorbidities and year .....	198
Figure 31: Predicted monthly cost in each line of therapy for first 18 months controlled for participant, death, comorbidities and year .....	199
Figure 32: Cost per month assuming no functional form over the months.....	200
Figure 33: Scheme of Chapter 6 .....	207
Figure 34: Schemata of trials and protocols.....	219
Figure 35: Systematic literature review of clinical studies involving multiple lines of therapy	224
Figure 36: Forest plot of meta-analysis results comparing overall response between initial and subsequent lines of therapy .....	233
Figure 37: Forest plot of meta-analysis results comparing disease control between initial and subsequent lines of therapy .....	234
Figure 38: Meta-analysis of relative risk of toxicity in subsequent line (compared to initial line) .....	239
Figure 39: Components of Chapter 7 .....	247
Figure 40: Context of decision-making for displacement.....	248
Figure 41: One-way sensitivity analysis of cost-effectiveness (lump sum model) (i=2).....	262
Figure 42: One-way sensitivity analysis of cost-effectiveness (lump sum model) (i=4).....	262
Figure 43: One-way sensitivity analysis of net monetary benefit (lump sum model) (i=2) .....	263
Figure 44: One-way sensitivity analysis of net monetary benefit (lump sum model) (i=4) .....	263
Figure 45: Scheme of the probabilistic sensitivity analysis .....	268
Figure 46: Cost-effectiveness acceptability curve for displacements .....	277
Figure 47: Cumulative probability of size of change in cost-effectiveness with displacement	278
Figure 48: Histogram of price reduction required to restore cost-effectiveness.....	279
Figure 49: One-way sensitivity analysis of cost-effectiveness (cost per day model) (i=2).....	509
Figure 50: One-way sensitivity analysis of cost-effectiveness (cost per day model) (i=4).....	510
Figure 51: One-way sensitivity analysis of net monetary benefit (cost per day model) (i=2)...	510
Figure 52: One-way sensitivity analysis of net monetary benefit (cost per day model) (i=4)...	511
Figure 53: One-way sensitivity analysis of cost-effectiveness (intermittent infusion) (i=2,4) ..	511

Figure 54: One-way sensitivity analysis of net monetary benefit (intermittent infusion) (i=2,4)	511
.....	
Figure 55: One-way sensitivity analysis of cost-effectiveness (FOLFOX model) (i=2,4) .....	512
Figure 56: One-way sensitivity analysis of net monetary benefit (FOLFOX model) (i=2,4) .....	512
Figure 57: One-way sensitivity analysis of cost-effectiveness (maintenance model) (i=2,4) ...	512
Figure 58: One-way sensitivity analysis of net monetary benefit (maintenance model) (i=2,4)	
.....	513

## List of tables

Table 1: Development of a treatment sequence from individual adoption decisions.....	14
Table 2: Displacement due to cetuximab in metastatic colorectal cancer .....	16
Table 3: Incremental cost-effectiveness analysis for three treatments in the first line of therapy .....	20
Table 4: Relationship between cost-effectiveness ratio, replacement and displacement decisions .....	26
Table 5: Incremental cost-effectiveness analysis for three treatments in the first line of therapy .....	35
Table 6: Incremental cost-effectiveness analysis for three treatments with displacement .....	38
Table 7: Incremental cost-effectiveness analysis for three treatments with displacement including intermediate treatment sequences .....	40
Table 8: Incremental cost-effectiveness analysis for three treatments with displacement and price adjustment .....	41
Table 9: Incremental cost-effectiveness analysis for three treatments with displacement including intermediate treatment sequences and price changes .....	42
Table 10: Search strategy for economic evaluations of treatment sequences in carcinomas....	49
Table 11: Recovered economic evaluations of multiple lines of therapy .....	52
Table 12: CHEERS checklist for economic evaluations of treatment sequences .....	56
Table 13: Alternatives and modelling for alternatives synthesised from a combination of sources.....	69
Table 14: Derivation of utility in economic evaluations of treatment sequences .....	71
Table 15: Implied impact on effectiveness of displacement in economic evaluations.....	73
Table 16: Included costs for recovered economic evaluations .....	76
Table 17: Implied cost changes for displaced treatments in the recovered economic evaluations .....	78
Table 18: Important clinical trials involving cetuximab.....	87
Table 19: Overview of included studies for the cetuximab economic evaluations.....	92
Table 20: CHEERS checklist for economic evaluations of cetuximab (not testing cost- effectiveness) .....	96
Table 21: Alternatives and use of other treatments in later line cetuximab economic evaluations .....	98
Table 22: Alternatives and use of other treatments in initial line cetuximab economic evaluations .....	102

Table 23: Characteristics of the EoCC cohort.....	117
Table 24: Characteristics and administrative data on the 232 EoCC participants with metastatic disease .....	117
Table 25: Mean number of treatments according to naïve oncologist’s review.....	121
Table 26: Estimated lines of therapy by new pharmaceutical use (oncologist’ review) .....	123
Table 27: Comparison between naïve oncologist’s review and new pharmaceutical use (oncologist’s review) for metastatic patients .....	123
Table 28: Breakdown of prescribed treatments (CPAP and general schedule) 2008-2011 by State .....	126
Table 29: Agreement between oncologist’s review and the PBS administrative data for metastatic protocols .....	129
Table 30: Cyclophosphamide supply in the EoCC cohort .....	133
Table 31: Potential scenarios of MBS and PBS chemotherapy identification .....	136
Table 32: Number of infusions without a PBS prescription by stage and site within 30, 60 and 100 days .....	139
Table 33: Metastatic cancer “excess” infusions by site and history of trastuzumab use.....	140
Table 34: Count of gap between successive “excess” infusions for metastatic breast cancer	141
Table 35: Gap between successive “excess” infusions for metastatic breast cancer by recorded use of trastuzumab .....	142
Table 36: Gap between successive “excess” infusions for metastatic CRC .....	143
Table 37: Use of supportive treatment and relationship to use of PBS chemotherapy.....	147
Table 38: Time from PBS chemotherapy items and MBS chemotherapy infusion item to the prescribing of aprepitant .....	148
Table 39: Time from PBS chemotherapy items and MBS chemotherapy infusion items to the prescribing of 5-HT3 receptor antagonists .....	148
Table 40: Hypothetical generation of lines of therapy in CRC.....	151
Table 41: Number of lines of therapy using the PBS method.....	154
Table 42: Differences in estimated number of lines of therapy between the PBS method and the oncologist’s review method .....	155
Table 43: Differences in estimated number of lines of therapy between PBS method and the new oncologist’s review with removal of specific pharmaceuticals and assumptions .....	156
Table 44: Differences in estimated number of prospective lines of therapy between the PBS method and the oncologist’s review .....	157

Table 45: Differences in estimated number of prospective lines of therapy between the PBS method and the oncologist’s review excluding trastuzumab .....	157
Table 46: Breakdown of lines of therapy by data extraction .....	158
Table 47: Breakdown of retrospective and prospective lines of therapy .....	166
Table 48: Total cost of admissions under different assumptions .....	171
Table 49: Most costly AR-DRG in the EoCC admitted data .....	171
Table 50: Total costs for EoCC participants with metastatic carcinoma of interest .....	175
Table 51: Costs of chemotherapy pharmaceutical and administration .....	176
Table 52: Total costs adjusting for censoring using inverse probability weighting.....	176
Table 53: Total costs adjusting for censoring using inverse probability weighting for the first two years in subgroups (Bang and Tsiatis estimator) .....	177
Table 54: Mean monthly costs and six-monthly total costs for each line of therapy .....	179
Table 55: Model selection without panel effects.....	191
Table 56: Model selection with panel effects .....	193
Table 57: Comparison of the coefficients across specifications.....	201
Table 58: Reduction in cost required .....	203
Table 59: Successful and initial unsuccessful applications for funding through the PBAC process for pharmaceuticals for metastatic cancer .....	215
Table 60: Protocols by year of approval via EViQ.....	216
Table 61: Details of literature search in Medline .....	223
Table 62: Recovered randomised control trials .....	226
Table 63: Type of information extracted from RCTs .....	229
Table 64: Quality of information extracted from the RCTs .....	231
Table 65: Odds ratio of response to treatment in a subsequent line of therapy (RCT and non-RCT) meta-analysis .....	235
Table 66: Sensitivity analysis for meta-analysis .....	235
Table 67: Association between PFS and displacement for RCTs.....	236
Table 68: Intensity of treatment in different lines of therapy .....	237
Table 69: Adverse event outcomes in RCTs .....	238
Table 70: Ratio of adverse events of CRC studies with PFS01 and PFS12 .....	239
Table 71: Comparison of mean pharmaceutical use with use associated with mean survival .	254
Table 72: Framework of models with altering marginal cost with time .....	256
Table 73: Model parameters .....	257
Table 74: Cost-effectiveness in different lines of therapy for fixed price protocol .....	261



Table 75: Cost-effectiveness of treatment assuming constant cost.....	264
Table 76: Cost-effectiveness of treatment assuming intermittent treatment model.....	265
Table 77: Cost-effectiveness of treatment (FOLFOX model) .....	265
Table 78: Cost-effectiveness of treatment (maintenance model).....	266
Table 79: Impact of discounting on the cost-effectiveness of displaced treatments.....	280
Table 80: Results of scenario analysis of PSA .....	281
Table 81: Inclusion and exclusion of publications of literature search of treatment sequences in carcinomas .....	296
Table 82: Construction of alternatives for treatment sequences in CRC .....	310
Table 83: Number of alternatives in each line of therapy .....	310
Table 84: CHEERS checklist for Hind et al. (2008) <sup>94</sup> .....	318
Table 85: CHEERS checklist for Miyazaki et al. (2009) <sup>93</sup> .....	320
Table 86: CHEERS checklist for Shirowa et al. (2009) <sup>95</sup> .....	321
Table 87: CHEERS checklist for Wong et al. (2009) <sup>1</sup> .....	323
Table 88: Data extraction for economic evaluations with synthesised alternatives, Wong et al. (2009) <sup>1</sup> .....	326
Table 89: CHEERS checklist for Manca et al. (2012) <sup>97</sup> .....	327
Table 90: CHEERS checklist for Tappenden et al. (2013) <sup>98</sup> .....	329
Table 91: Data extraction for economic evaluations with synthesised alternatives, Tappenden et al. (2013) <sup>98</sup> .....	331
Table 92: CHEERS checklist for Rautenberg et al. (2014) <sup>2</sup> .....	332
Table 93: Data extraction for economic evaluations with synthesised alternatives, Rautenberg et al. (2014) <sup>2</sup> .....	334
Table 94: CHEERS checklist for Goldstein et al. (2015) <sup>89</sup> .....	334
Table 95: CHEERS checklist for Riesco-Martinez et al. (2016) <sup>4</sup> .....	336
Table 96: Data extraction for economic evaluations with synthesised alternatives, Riesco-Martinez et al. (2016) <sup>4</sup> .....	338
Table 97: CHEERS checklist for NICE (2009) <sup>90</sup> .....	339
Table 98: Data extraction for economic evaluations with synthesised alternatives, NICE (2009) <sup>90</sup> .....	340
Table 99: CHEERS checklist for Chouaid et al. (2012) .....	341
Table 100: CHEERS checklist for Chouaid et al. (2013) .....	343
Table 101: Economic Evaluations of cetuximab later lines of therapy.....	351
Table 102: CHEERS checklist for Norum (2006) .....	356

Table 103: CHEERS checklist for Annemans et al. (2007) <sup>141</sup> .....	357
Table 104: CHEERS checklist for Starling et al. (2007) <sup>142</sup> .....	358
Table 105: CHEERS checklist for Tappenden et al. (2007) <sup>136</sup> .....	360
Table 106: CHEERS checklist for Mittmann et al. (2009) <sup>129</sup> .....	361
Table 107: CHEERS checklist for Health Quality Ontario (2010) <sup>3</sup> .....	363
Table 108: CHEERS checklist for Shiroiwa et al. (2010) <sup>143</sup> .....	365
Table 109: CHEERS checklist for Blank et al. (2011) <sup>145</sup> .....	366
Table 110: CHEERS checklist for Fragoulakis et al. (2012) <sup>146</sup> .....	368
Table 111: CHEERS checklist for Vijayaraghaven et al. (2012) <sup>147</sup> .....	369
Table 112: CHEERS checklist for Hoyle et al. (2013) <sup>137</sup> .....	371
Table 113: CHEERS checklist for Asseburg et al. (2011) <sup>144</sup> .....	375
Table 114: CHEERS checklist for Lawrence et al. (2013) <sup>148</sup> .....	376
Table 115: CHEERS checklist for Barone et al. (2014) <sup>149</sup> .....	377
Table 116: CHEERS checklist for Westwood et al. (2014) <sup>86</sup> .....	379
Table 117: CHEERS checklist for Graham et al. (2015) <sup>150</sup> .....	381
Table 118: CHEERS checklist for Wen et al. (2015) <sup>151</sup> .....	382
Table 119: Economic evaluations of cetuximab as the first line of therapy .....	384
Table 120: CHEERS checklist for Behl et al. (2012) <sup>125</sup> .....	389
Table 121: Economic evaluations of cetuximab involving treatment sequences .....	390
Table 122: Model specifications for the econometric analysis .....	392
Table 123: Unaltered costs ordinary least squares models 1 to 7 .....	393
Table 124: Unaltered costs ordinary least squares models 8 to 14 .....	396
Table 125: Logged costs ordinary least squares models 1 to 7 .....	399
Table 126: Logged costs ordinary least squares models 8 to 14 .....	402
Table 127: Coefficients for fixed and random effects with unaltered costs as the dependent variable .....	405
Table 128: Coefficients for fixed and random effects with logged costs as the dependent variable .....	408
Table 129: Summary of full-text review of literature search for studies with two or more lines of therapy .....	411
Table 130: Flow of Medline search .....	413
Table 131: Full-text review of Medline search .....	413
Table 132: Recovered literature from pearl search of recovered Medline articles .....	424
Table 133: Results of EconLit search .....	427

Table 134: Results of full-text review of EconLit recovered articles.....	428
Table 135: Additional articles recovered from ‘pearl’ searching for recovered EconLit articles .....	432
Table 136: PubMed search .....	433
Table 137: Inclusion and exclusions of PubMed search .....	434
Table 138: Pearl searched articles from PubMed search .....	441
Table 139: Trial arms for Tournigand et al. (2004) <sup>68</sup> .....	443
Table 140: CONSORT quality checklist for Tournigand et al. (2004) <sup>68</sup> .....	444
Table 141: Quality of comparison information in Tournigand et al. (2004) <sup>68</sup> .....	445
Table 142: Outcome results for Tournigand et al. (2004) <sup>68</sup> .....	446
Table 143: Toxicity of FOLFIRI in Tournigand et al. (2004) <sup>68</sup> .....	447
Table 144: Toxicity of FOLFOX in Tournigand et al. (2004) <sup>68</sup> .....	447
Table 145: CONSORT quality checklist for Manegold et al. (2005) <sup>254</sup> .....	448
Table 146: Quality checklist for data extraction for Manegold et al. (2005) <sup>254</sup> .....	450
Table 147: Outcome results for Mangold et al. (2005) <sup>254</sup> .....	451
Table 148: Trial arms for Koopman et al. (2007) <sup>71</sup> .....	452
Table 149: CONSORT quality checklist for Koopman et al. (2007) <sup>71</sup> .....	452
Table 150: Quality checklist for data extraction for Koopman et al. (2007) <sup>71</sup> .....	454
Table 151: Outcome results for Koopman et al. (2007) <sup>71</sup> .....	455
Table 152: Trial arms for Seymour et al. (2007) <sup>72</sup> .....	456
Table 153: CONSORT quality checklist for Seymour et al. (2007) <sup>72</sup> .....	456
Table 154: Quality checklist for data extraction for Seymour et al. (2007) <sup>72</sup> .....	459
Table 155: Outcome results for Seymour et al. (2007) <sup>72</sup> .....	459
Table 156: Toxicity of FOLFIRI in Seymour et al. (2007) <sup>72</sup> .....	460
Table 157: Toxicity of FOLFOX in Seymour et al. (2007) <sup>72</sup> .....	460
Table 158: Trial arms for Dahan et al. (2010) <sup>255</sup> .....	461
Table 159: CONSORT quality checklist for Dahan et al. (2010) <sup>255</sup> .....	461
Table 160: Quality checklist for data extraction for Dahan et al. (2010) <sup>255</sup> .....	463
Table 161: Outcome results for Dahan et al. (2010) <sup>255</sup> .....	463
Table 162: Toxicity of gemcitabine in Dahan et al. (2010) <sup>255</sup> .....	464
Table 163: Toxicity of cisplatin in Dahan et al. (2010) <sup>255</sup> .....	465
Table 164: Trial arms for Ducreux et al. (2011) <sup>256</sup> .....	465
Table 165: CONSORT quality checklist for Ducreux et al. (2011) <sup>256</sup> .....	466
Table 166: Quality checklist for data extraction Ducreux et al. (2011) <sup>256</sup> .....	467

Table 167: Outcome results for Ducreux et al. (2011) <sup>256</sup> .....	468
Table 168: Toxicity of FOLFOX in Ducreux et al. (2011) <sup>256</sup> .....	469
Table 169: Toxicity of FOLFIRI in Ducreux et al. (2011) <sup>256</sup> .....	469
Table 170: Trial arms for Kim et al. (2011) <sup>257</sup> .....	470
Table 171: CONSORT quality checklist for Kim et al. (2011) <sup>257</sup> .....	470
Table 172: Quality checklist for data extraction for Kim et al. (2011) <sup>257</sup> .....	472
Table 173: Outcome results for Kim et al. (2011) <sup>257</sup> .....	472
Table 174: Trial arms of Le Caer et al. (2011) <sup>100</sup> .....	474
Table 175: CONSORT quality checklist for Le Caer et al. (2011) .....	474
Table 176: Quality checklist for data extraction for Le Caer et al. (2011) .....	476
Table 177: Outcome results for Le Caer et al. (2011) <sup>100</sup> .....	476
Table 178: Toxicity of gemcitabine in Le Caer et al. (2011) <sup>100</sup> .....	477
Table 179: Toxicity of erlotinib in Le Caer et al. (2011) <sup>100</sup> .....	477
Table 180: Trial arms for Gridelli et al. (2012) <sup>258</sup> .....	478
Table 181: CONSORT quality checklist for Gridelli et al. (2012) <sup>258</sup> .....	478
Table 182: Quality checklist for data extraction for Gridelli et al. (2012) <sup>258</sup> .....	480
Table 183: Outcome results for Gridelli et al. (2012) <sup>258</sup> .....	481
Table 184: Trial arms for Le Caer et al. (2012) <sup>99</sup> .....	482
Table 185: CONSORT quality checklist for Le Caer et al. (2012) <sup>99</sup> .....	482
Table 186: Quality checklist for data extraction for Le Caer et al. (2012) <sup>99</sup> .....	484
Table 187: Outcome results for Le Caer et al. (2012) .....	484
Table 188: Toxicity of gemcitabine in Le Caer et al. (2012) <sup>99</sup> .....	485
Table 189: Toxicity of erlotinib in Le Caer et al. (2012) <sup>99</sup> .....	485
Table 190: Trial arms of Eichelberg et al. (2015) <sup>118</sup> .....	485
Table 191: CONSORT quality checklist for Eichelberg et al. (2015) <sup>118</sup> .....	486
Table 192: Quality checklist for data extraction for Eichelberg et al. (2015) <sup>118</sup> .....	487
Table 193: Outcome results for Eichelberg et al. (2015) <sup>118</sup> .....	488
Table 194: Toxicity of sorafenib in Eichelberg et al. (2015) <sup>118</sup> .....	488
Table 195: Toxicity of sunitinib in Eichelberg et al. (2015) <sup>118</sup> .....	489
Table 196: Trial arms of Knox et al. (2017) <sup>253</sup> .....	489
Table 197: CONSORT quality checklist for Knox et al. (2017) <sup>253</sup> .....	489
Table 198: Quality checklist for data extraction for Knox et al. (2017) <sup>253</sup> .....	491
Table 199: Outcome results for Knox et al. (2017) <sup>253</sup> .....	491
Table 200: Toxicity of everolimus in Knox et al. (2017) <sup>253</sup> .....	492

Table 201: Toxicity of sunitinib in Knox et al. (2017) <sup>253</sup> .....	492
Table 202: Non-RCT included in literature review .....	494
Table 203: Information extracted from non-RCTs .....	496
Table 204: Information from Dupont (2006) <sup>245</sup> .....	498
Table 205: Information from Michels et al. (2006) <sup>264</sup> .....	499
Table 206: Information from Oh et al. (2006) <sup>260</sup> .....	499
Table 207: Information from Popov et al. (2006) <sup>265</sup> .....	500
Table 208: Information from Sakar et al. (2007) <sup>596</sup> .....	500
Table 209: Toxicity of XELIRI in Sakar et al. (2007) <sup>596</sup> .....	500
Table 210: Toxicity of XELOX in Sakar et al. (2007) <sup>596</sup> .....	501
Table 211: Information from Joung et al. (2008) <sup>647</sup> .....	501
Table 212: Information from Dudek et al. (2009) <sup>646</sup> .....	502
Table 213: Information from Sablin et al. (2009) <sup>645</sup> .....	503
Table 214: Information from Agelaki et al. (2010) <sup>266</sup> .....	503
Table 215: Information from Busch et al. (2011) <sup>581</sup> .....	504
Table 216: Information from Herrmann et al. (2011) <sup>643</sup> .....	504
Table 217: Information from Park et al. (2011) <sup>642</sup> .....	504
Table 218: Information from Porta et al. (2011) <sup>262</sup> .....	505
Table 219: Information from Buchler et al. (2012) <sup>641</sup> .....	505
Table 220: Information from Hong et al. (2012) <sup>574</sup> .....	506
Table 221: Information from Stenner et al. (2012) <sup>261</sup> .....	506
Table 222: Information from Busch et al. (2013) <sup>637</sup> .....	507
Table 223: Information from Fiala et al. (2013) <sup>636</sup> .....	508
Table 224: Information from Alimohamed et al. (2014) <sup>655</sup> .....	508
Table 225: Parameters and model inputs for probabilistic sensitivity analysis.....	514

## Abstract

### Background

Medical technology is increasing the number of available treatments for cancer. For advanced cancer an increasing number of treatments can result in an increasing treatment sequence. Treatments are given one after another in a cycle of treatment, failure and then another treatment. Newly added treatments may not replace existing treatments. The movement of existing treatments into later lines of therapy is displacement.

Displacement poses challenges for economic evaluation. This thesis addresses three questions.

1. Does the displacement of a treatment alter its cost-effectiveness?
2. If the cost-effectiveness becomes less favourable can any resulting societal welfare loss be corrected by changing the price?
3. Can the required price change be calculated in Australia?

### Methods

A theoretical framework is developed for displacement in cancer treatment. The implications of decision-making criteria and information gaps are assessed. Real-world data is used to estimate the number of treatments and lines of therapy received by patients, and costs of care. A systematic review and meta-analysis of randomised controlled trials which reported treatment outcomes of multiple lines of therapy is undertaken. The cost-effectiveness of displacing treatments for breast cancer, colorectal cancer and non-small cell lung cancer are modelled.

### Results

The displacement of a treatment may result in dynamic and allocative inefficiencies.

Real-world data showed 13-18% of participants received four or more lines of therapy. The mean health services cost of cancer care was approximately \$4 000 per month. Displacement resulted in decreased effectiveness, an increased toxicity per unit time and reduced treatment length.

In the modelling, there was an increase in the incremental cost-effectiveness ratio with displacement. After displacement, reducing the price of cancer treatments by 32% was required to restore cost-effectiveness.

## Conclusions

There is the potential for displacement in Australia. Displacement results in an increasing incremental cost-effectiveness ratio of a treatment. This can be corrected with price changes in most circumstances.

The Australian real-world data did not record all the treatments that were received by patients. Therefore, it is not able to be used to calculate the price changes that are required with displacement.

The addition of new treatments in Australia should consider the impact of displacement on currently subsidised treatments. A failure to do this results in biased assessments of the benefits and costs of new treatments. It will likely underestimate the cost and overestimate the benefit. Therefore, the potential for displacement should be considered in cancer treatment funding to ensure equity and cost-effectiveness.

## Abbreviations

Abbreviation	Full-text
5-FU	5-fluorouracil
5-HT3	5-hydroxytryptamine 3 (receptor antagonist)
AC	a protocol consisting of doxorubicin and cyclophosphamide
ACIM	Australian Cancer Incidence and Mortality (Books)
AIC	Akaike information criterion
AIHW	Australian Institute of Health and Welfare
AR-DRG	Australian Refined Diagnosis Related Groups
ASM	additive separate model
ATC	Anatomical Therapeutic Chemical Classification System
AUD	Australian dollar
Aus.	Australian
BSC	best supportive care
C/E	cost-effectiveness
Ca	Cancer
Cet	Cetuximab
Cet+I	cetuximab and irinotecan
CHEERS	consolidated health economics reporting
CHeReL	Centre for Health Record Linkage
CI	confidence interval
CONSORT	Consolidated Standards of Reporting Trials
CPAP	Chemotherapy Pharmaceutical Access Program
CRC	colorectal cancer
CTCAE	common terminology criteria for adverse events
D	Docetaxel
DC	disease control
DEALE	Declining Exponential Approximation of Life Expectancy
DRG	Diagnostic Related Groups
ED	emergency department
EGFR	epithelial growth factor receptor
EM-CaP	Economic Models of Cancer Protocols research project
EoCC	Elements of Cancer Care
EQ-5D	European Quality of life-5 Dimensions
EViQ	Cancer Treatments Online
FEC	a protocol consisting of 5-fluorouracil, epirubicin and cyclophosphamide
FOCUS (trial)	fluorouracil, oxaliplatin, CPT11: use and sequencing
FOLFIRI	a protocol consisting of 5-fluorouracil, leucovorin and irinotecan
FOLFOX	a protocol consisting of 5-fluorouracil, leucovorin and oxaliplatin
G-CSF	granulocyte-colony stimulating factor



Gem	gemcitabine
Gem and Carbo	a protocol consisting of gemcitabine and carboplatin
HCD	high cost drug
HR	hazard ratio
HTA	Health Technology Assessment
HUI3	Health Utilities Index Mark 3
ICER	incremental cost-effectiveness ratio
IHPA	Independent Hospital Pricing Authority
IV	intravenous
KRAS	Kristen rat sarcoma
LYS	life year saved
MBS	Medical Benefits Schedule
Met	metastatic
MRC	Medical Research Council
N/A	not applicable
NCCN	National Comprehensive Cancer Network
NHCDC	National Hospital Costs Data Collection
NHMRC	National Health and Medical Research Council
NHS	National Health Service
NICE	National Institute of Health and Clinical Excellence
NMB	net monetary benefit
NSCLC	non-small cell lung cancer
NSW	New South Wales
Onc	oncologist
OR	odds ratio
OR	overall response
OS	overall survival
P	price
PBAC	Pharmaceutical Benefits Advisory Committee
PBS	Pharmaceutical Benefits Scheme
PFS	progression free survival
Pharm	pharmaceutical
PPP	purchasing power parity
PSA	probabilistic sensitivity analysis
Q	quantity
QALY	quality adjusted life years
QHES	Quality of Health Economics Studies
RCC	renal cell carcinoma
RCT	randomised controlled trial
RECIST	Response evaluation criteria in solid tumours
RPBS	Repatriation Schedule of Pharmaceutical Benefits
RR	relative risk

s100	section 100
SD	standard deviation
SPP	survival post-progression
STROBE	Strengthening the Reporting of Observational Studies in Epidemiology
TGA	Therapeutic Goods Administration
TNM	Tumour Node Metastasis staging system
UK	United Kingdom
US(A)	United States of America
USD	United States of America dollars
XELIRI	a protocol consisting of irinotecan and capecitabine
XELOX	a protocol consisting of oxaliplatin and capecitabine

## Symbols

Abbreviation	Full-text
\$	dollar
%	per cent
g	gram
K	thousand
kg	kilogram
M	million
mg	milligram
mm	millimetre

